Summary An in vitro model of acquired melphalan resistance was developed by serial incubation of an MCF-7 human breast cancer cell line in increasing concentrations of melphalan. The Alkylating agent therapy is central to the chemotherapeutic approach to most malignancies, yet relatively few mechanisms of alkylating agent resistance have been described. In particular, while transport-mediated resistance has been wellcharacterised for many antineoplastic agents, most notably the multidrug resistance phenotype associated with the drug efflux pump P-glycoprotein, little is known about mechanisms of uptake, accumulation and efflux of alkylating agents. Cellular resistance to alkylating agents has generally been attributed to mechanisms which either detoxify the agent or repair its damage.
Alkylating agent therapy is central to the chemotherapeutic approach to most malignancies, yet relatively few mechanisms of alkylating agent resistance have been described. In particular, while transport-mediated resistance has been wellcharacterised for many antineoplastic agents, most notably the multidrug resistance phenotype associated with the drug efflux pump P-glycoprotein, little is known about mechanisms of uptake, accumulation and efflux of alkylating agents. Cellular resistance to alkylating agents has generally been attributed to mechanisms which either detoxify the agent or repair its damage.
Melphalan (1-phenylalanine mustard, L-PAM, Alkeran) is a rationally designed alkylating agent which incorporates the amino acid phenylalanine as a part of its structure. Melphalan is active against ovarian cancer, myeloma, breast cancer and rhabdomyosarcoma. Most in vitro models of melphalan resistance have involved glutathione-mediated pathways, a finding observed in a wide variety of rodent cell lines including Chinese hamster ovary (Begleiter et al., 1983) and murine L1210 leukaemia cells (Ahmad et al., 1987a; Ahmad et al., 1987b) ; and human cell lines, including ovarian (Green et al., 1984) , myeloma (Gupta et al., 1989; Bellamy et al., 1991) and prostate (Bailey et al., 1992) cells.
In this report we characterise a melphalan resistant MCF-7 human breast cancer cell line (Mel R MCF-7) which was isolated by serial incubation of the parental cell line in increasing concentrations of melphalan. This model of melphalan resistance differs from other human in vitro models of melphalan resistance in that the MelR MCF-7 cells have a significant defect in melphalan uptake associated with their resistance. In addition, unlike most other melphalan resistant cell lines reported, MelR MCF-7 cells have not developed changes in glutathione and glutathione-dependent pathways.
Materials and methods
Cell and culture conditions WT MCF-7 and MelR MCF-7 cells were grown in Improved Minimal Essential Medium (IMEM) with (Gibco) and 5% (vol/vol) foetal calf serum (Gibco) as previously described (Batist et al., 1986) . Cells were maintained at 37°C in a 5% C02-95% air atmosphere. MelR MCF-7 cells were grown in drug-free medium for at least 1 week and as long as 2 months prior to cytotoxicity and drug accumulation studies.
Cytotoxicity and growth assays A semi-automated sulforhodamine dye-based microtiter-plate assay was used for cytotoxicity and growth assays. WT MCF-7 (3,000 cells/well) and MelR MCF-7 (6,000 cells/well) were plated into 96-well microtiter plates in 100 ,l of IMEM with 5% foetal calf serum. On the following day, serial dilutions of melphalan were added in another 100 ftI medium.
The duration of exposure to melphalan was limited by the relatively brief half-life of the drug; in infusion fluids, the t1/2 of melphalan at 37°C is approximately 3 h (Tabibi & Cradock, 1984) . On the fifth day, the cells were fixed with 50yl of 50% tricarboxylic acid for 1 h at 4'C, washed with water and allowed to air dry, stained with 0.4% sulforhodamine in 1% acetic acid for 10 min, washed five times with 1% acetic acid and allowed to dry (Skehan et al., 1990) . The stained cells were solubilised in 10 mm Tris base pH 10.5, and the absorbance at 540 nm was determined on a microplate reader (Skehan et al., 1990 values. All cytotoxicity assays were performed at least three separate times in triplicate. Cytotoxicity assays involving BSO were performed by adding 100 tLM BSO to cells 4 h after plating and 24h prior to the addition of melphalan. This exposure to BSO is comparable to that reported to significantly decrease glutathione levels in multidrug resistant MCF-7 cells (Kramer et al., 1988; Dusre et al., 1989) .
Growth assays were also performed with the sulforhodamine technique. Cells were plated in medium in 96 well microtiter plates, and stained and fixed every 24 h. Doubling times were derived from the slopes of the linear part of each of the growth curves.
Transport studies Melphalan uptake studies were performed as follows: WT MCF-7 and MelR MCF-7 cells were plated in either 6-or 12-well Linbro dishes. Approximately 48 h after plating, during the exponential growth phase, the cells were washed three times with PAG transport medium (Dulbecco's phosphate buffered saline containing 6.8 g 1`albumin and 1 g 1'-glucose) pre-warmed to 37°C. Transport medium containing
[14C] melphalan (Moravek) was then added to the cells and incubated at 37°C for the specified time. At the end of the uptake period, the medium was quickly aspirated, and the plates were immersed in four consecutive baths of ice-cold Dulbecco's phosphate buffered saline in rapid succession. The plates were blotted dry, and the cells were solubilised by overnight incubation in 0.2 N NaOH at room temperature. The cell lysates were neutralised with 0.2 N HCI and the radioactivity determined by liquid scintillation counting. Amino acids used for transport inhibition studies were obtained from Gibco and BCH was obtained from Calbiochem. Competitors were added to the transport medium containing radiolabelled melphalan, so that cells were simultaneously exposed to radiolabelled melphalan and excess unlabelled competitor. Melphalan uptake at 0°C was minimal (less than 5% of the uptake at 37°C; Figure 2 ). The uptake at 0°C was determined and subtracted from the uptake measured at 37°C for each Lineweaver-Burke plot data point.
For uptake studies, the total number of cells was determined in replicate plates. Cells were trypsinised, resuspended in medium, passed several times through a 19 gauge needle to make a single cell suspension, diluted in isotonic buffered saline, and counted in a Coulter counter.
Protein studies
Cytosolic glutathione S-transferase activity was determined by using 1-chloro-2,4 dinitrobenzene as substrate (Habig & Jakoby, 1981) . One unit of glutathione S-transferase enzyme activity is defined as the amount catalysing the conjugation of the substrate with glutathione at the rate of 1 nmol min-'.
Total glutathione levels were determined on cell cytosol by the cyclic reduction of oxidised glutathione with glutathione reductase and NADPH as described by Tietze (1969) .
Cytosolic protein was extracted from washed cells by sonication and centrifugation of the cell pellet, and the protein concentration of the cytosols was determined spectrophotometrically using Coomassie Plus protein assay reagent (Pierce).
Nucleic acid studies
For Northern analysis, RNA was isolated by guanidine isothiocyanate-cesium chloride gradient centrifugation (Sambrook et al., 1989) and the concentration was determined by spectrophotometry. The RNA samples (10 pg) were size fractionated on a 1% agarose gel that contained 2% formaldehyde using a buffer consisting of 20 mM MOPS containing 1 mM EDTA and 5 mM sodium acetate. Equivalence of RNA loading of the samples was confirmed by ethidium bromide staining of the gel. The RNA was transferred onto a Nytran membrane (Schleicher & Schuell), baked 2 h in an 80°C vacuum oven and hydridised overnight with a [32p]_ labelled cDNA probe for GSTP-1 (GSTn-1; Moscow et al., 1988) . The blot was washed with a final stringency of 0.1 x SSC and 0.1% SDS at 65°C and hybridisation was detected by autoradiography.
Results
Selection of melphalan resistant MCF-7 cells Melphalan resistant MCF-7 cells were developed by serial incubation of MCF-7 cells in increasing concentrations of melphalan as described in Methods. The melphalan doseresponse curve of the resulting subline, MelR MCF-7, is shown in Figure 1 . The melphalan IC,0 of Mel R MCF-7 cells is 52 ZlM, compared to 1.7 J.M for WT MCF-7 cells.
Thus, MelR MCF-7 cells are 30-fold resistant to melphalan at the IC50 level.
MelR MCF-7 cells have a lower plating efficiency than WT MCF-7 cells, 31 ± 1% and 51 ± 7% respectively. In addition, MeIR MCF-7 cells grow slower than WT MCF-7 cells, with a doubling time of 47 ± 3 h vs 27 ± 1 h for Mel R MCF-7 and WT MCF-7 cells respectively. MeIR MCF-7 cells contain slightly more cytosolic protein per cell than the parental cell line (101 ± 7 vs 80 ± 1 jg 10-6 cells).
Resistance to melphalan in MelR MCF-7 cells gradually declined when the cells were maintained in the absence of drug. After 2 months passage in the absence of drug, resis- Melphalan [>M] Figure comparison to WT MCF-7 cells. The uptake appears to be linear over the first 6min, and then reaches a plateau by 20 min. The time over which linear uptake occurs is longer than that observed in L1210 cells (Redwood & Colvin, 1980) , but comparable to that previously observed in MCF-7 cells (Begleiter et al., 1980) . Melphalan uptake at 4°C was minimal ( Figure 2 ). An inverse-reciprocal plot of melphalan uptake at 2 min over a concentration range of 1-300 IM is shown in Figure  3 . The Kt and Vmax for melphalan for each cell line was determined by linear regression analysis. For WT MCF-7 cells, the apparent Kt was 70 1LM and the Vmax was 2110amolcell-1min-'. For MeIR MCF-7 cells, the Kt was 36f1M and the Vmax was 516amolcell-1min-'. Therefore, while there may be some qualitative changes in the apparent Kt, the major difference between Mel R MCF-7 and WT MCF-7 cell lines appears to be related to the 4-fold decrease in the Vmax.
Previous studies of melphalan uptake have attributed melphalan uptake to two amino acid transport systems (Goldenberg et al., 1979; reviewed by Vistica, 1983) . One transporter is similar to the amino acid transport System L which preferentially transports leucine, but also transports phenylalanine, tyrosine, tryptophan and valine. System L is inhibited by the synthetic inert amino acid BCH and is sodium independent. The other transporter is similar, if not identical, to System ASC (for alanine, serine, cysteine) which is sodium dependent and unaffected by BCH. In order to determine which amino acid transport system was responsible for melphalan uptake in WT MCF-7 and Mel R MCF-7 cells, we examined initial uptake in the absence of sodium and in the presence of BCH. Initial melphalan (100 JIM) uptake when choline was substituted for sodium in the transport medium was 102 ± 1% in WT MCF-7 cells, and 81 ± 9% in MelR MCF-7 cells relative to uptake of drug measured in PAG transport medium. Thus, a sodium-independent mechanism accounts for most, if not all, of the melphalan transport in both WT MCF-7 and MelR MCF-7 cells.
The effect of BCH inhibition of melphalan uptake is shown in Figure 4 . As can be seen by the inverse reciprocal plots, 1 mM BCH eliminates the difference between MelR MCF-7 and WT MCF-7 cells in the initial melphalan uptake over the concentration range of 3 to 30 JiM. This finding suggests that the difference in melphalan uptake between the two cell lines can be ascribed to an alteration in the System L transporter. BCH competition studies, seen in both Figures 4 and 5, also demonstrate that non-System L-mediated transport is a small but significant mechanism of melphalan uptake in both cell lines.
Melphalan uptake competition studies in the presence of excess unlabelled amino acids ( Figure 5 ) supports the importance of the System L transporter in the two cell lines. System L substrates, such as leucine, phenylalanine, tyrosine and tryptophan, were more effective in inhibiting initial melphalan uptake than the amino acids which are poor sub- strates for System L, such as arginine, cystine and serine (Christensen, 1990) .
Melphalan efflux was examined in both cell lines after incubation in radiolabelled melphalan. As shown in Figure 6 , there was no difference in melphalan efflux between the two cell lines after the initial loading period. Therefore, drug efflux does not appear to contribute to the decreased melphalan accumulation seen in MelR MCF-7 cells.
Glutathione-dependent detoxification
We examined MelR MCF-7 cells for alterations in glutathione and its dependent enzymes. As shown in Table I , there was no significant difference between the two cell lines in either glutathione content or glutathione S-transferase activity. A Northern analysis of the expression of GSTPI-l RNA is shown in Figure 7 . There was no detectable expression of GSTPI-l RNA in either cell line.
Most, if not all, melphalan-resistant cell lines with alterations in glutathione-dependent pathways demonstrate reversal of resistance with BSO, a glutathione synthesis inhibitor. The effect of preincubation of WT MCF-7 and MeIR MCF-7 cells with BSO on melphalan cytotoxicity is shown in Figure 8 . BSO did not specifically reverse the melphalan resistance of MelR MCF-7 cells, indicating that melphalan resistance in Mel R MCF-7 cells is not mediated by glutathione-dependent pathways.
Discussion
We have isolated a melphalan resistant MCF-7 human breast cancer cell line by serial incubation of MCF-7 cells in increasing concentrations of melphalan. The resulting cell line, MelR MCF-7, is 30-fold resistant to melphalan. Characterisation of this cell line has revealed that resistance is associated with a decrease in melphalan accumulation resulting from diminished accumulation of drug, and that glutathione-dependent mechanisms apparently are not responsible for the acquired resistance seen in MelR MCF-7 cells. It is possible that other unidentified mechanisms of melphalan resistance co-exist with decreased melphalan transport in MelR MCF-7 cells.
A study by Begleiter et al. (1980) GSTw - Figure 7 Northern analysis of GSTPI-l (GSTn) RNA expression in MelR MCF-7 cells. Ten ig of RNA was probed for expression of GSTPl-l RNA as described in Materials and methods. RNA from the multidrug resistant MCF-7 subline AdrR MCF-7, which overexpresses GSTPI-l (Batist, 1986 ) was used for a positive control. reports, 700 amol cell-' min-' vs 2110 amol cell-' min-' in this study. In both studies, there is evidence that melphalan uptake is mediated by at least two different transport systems, one which is BCH-sensitive and which accounts for most melphalan uptake at low ( 30 pM) melphalan concentrations, and a BCH-insensitive system. Although the BCHinsensitive system resembled system ASC in the report by Begleiter et al. (1980) , in that melphalan uptake in their MCF-7 cell line was both partially sodium-dependent and inhibited by glutamine excess, in our study we found no evidence of sodium-dependent melphalan uptake in WT MCF-7 cells.
Several studies have previously demonstrated an association between altered system L transport and melphalan resistance. Redwood and Colvin (1980) reported an in vivo model of melphalan resistance in a murine L1210 leukaemia cell line selected for melphalan resistance while grown intraperitoneal in mice. Strikingly, the L1210 cell lines displayed a response to BCH inhibition of system L virtually identical to that seen in MelR MCF-7 cells. These parallel observations are even more remarkable considering the fact that the Vmax in WT MCF-7 cells is 10-to 80-fold higher than the Vmax reported for L1210 cells.
Using an alternative approach, Dantzig et al. (1984) isolated a Chinese hamster ovary cell line with defective system L transport by selecting cells with slow growth characteristics after treatment with a mutagen and exposure to medium containing relatively low concentrations of leucine. A single isolated clone demonstrated decreased uptake of system L substrates and relative melphalan resistance under drug exposure conditions designed to limit non-system L melphalan uptake.
Two human medulloblastoma cell lines with differences in relative sensitivity to melphalan have been compared to each with respect to melphalan transport and glutathione-related characteristics (Friedman et al., 1988) . The comparison of these cell lines indicated an association between melphalan resistance and a decreased Vmax for melphalan, although both system L and system ASC were functional in these cell lines.
Enhanced melphalan efflux has also been associated with melphalan resistance. Analysis of a Chinese hamster ovary cell line selected for colchicine resistance and found to be cross-resistant to melphalan (Elliot & Ling, 1981) revealed that decreased melphalan accumulation resulted from enhanced melphalan efflux (Begleiter et al., 1983) . However, analysis of melphalan efflux from WT MCF-7 and MelR MCF-7 cells in the presence of PAG transport medium ( Figure 6 ) revealed no differences between the WT MCF-7 cells and the resistant subline. Melphalan efflux is a complicated process which can be affected by the concentrations of extracellular amino acids (Begleiter et al., 1982; Vistica & Schuette, 1981) . However, the sensitive and resistant cell lines did not differ in the rate of efflux when incubated in amino acid replete IMEM growth medium after initial melphalan loading (data not shown).
MelR MCF-7 cells therefore represent the first in vitro model of transport-associated melphalan resistance in a human cell line selected for resistance to melphalan. This cell line also demonstrates that altered system L-mediated transport may be a relevant mechanism of acquired resistance to melphalan in human tumours. In contrast to system ASC, system L-mediated transport appears to be responsible for acquired resistance in every model of melphalan resistance in which melphalan uptake is impaired. Therefore, augmentation of system L capacity may be an appropriate strategy for circumventing melpahalan resistance or increasing melphalan cytotoxicity.
Glutathione and glutathione-dependent enzymes have frequently been associated with melphalan resistance. Increased glutathione levels have been observed in a wide variety of cell lines selected for melphalan resistance (Ahmad et al., 1987a; Bailey et al., 1992; Bellamy et al., 1991; Green et al., 1984; Rosenberg et al., 1989; Schecter et al., 1991) . Two other models of melphalan resistance have been reported in which no increase in glutathione content was found in the resistant cell lines (Friedman et al., 1988; Gupta et al., 1989) . In cell lines that demonstrate an increase in glutathione levels, BSO has been found to consistently reverse melphalan resistance (Ahmad et al., 1987a; Bellamy et al., 1991; Green et al., 1984; Rosenberg et al., 1989) .
The involvement of GSTs in melphalan resistance was suggested by biochemical studies which demonstrated that GSTs could conjugate melphalan to 4-(glutathionyl)phenylalanine (Dulick & Fenselau, 1987) . The association between GSTs and models of melphalan resistance has been inconsistent, with an increase in GST activity reported in two cell lines (Gupta et al., 1989; Schecter et al., 1991) but not in others (Friedman et al., 1988; Rosenberg et al., 1989) . In the models of melphalan resistance in which GST activity was elevated, the increase has been associated with an increase in the pi-class (Gupta et al., 1989; Schecter et al., 1991) and alpha class (Schecter et al., 1991) GST isozymes. However, the greatest level of melphalan resistance conferred by transfection of pi and alpha class GST genes was 1.5-fold (Puchalski & Fahl, 1990) , while other studies showed no acquisition of melphalan resistance in GST transfected clones (LeylandJones et al., 1991; Moscow et al., 1989; Nakagawa et al., 1990) . Two other glutathione dependent enzymes have also been associated with melphalan resistance, gamma glutamyl transpeptidase (Ahmad et al., 1987b) and gamma glutamyl cysteine synthetase (Bailey et al., 1992) .
Clinical trials combining BSO and melphalan are currently underway. The use of BSO to decrease glutathione levels and enhance its antineoplastic cytotoxicity has been successful not only in vitro, but also in animal models (Friedman et al., 1989; Kramer et al., 1987) . Unfortunately, normal cells may also employ glutathione-mediated defences, and BSO can add to melphalan mediated host toxicity (Smith et al., 1989) . BSO may not be effective in clinical trials if it does not increase the therapeutic index of melphalan, or alternatively, if malignant tumours develop mechanisms of resistance to melphalan that are not glutathione-dependent. For example, neither of the in vitro models of melphalan resistance in MCF-7 human breast cancer cells, the study presented here and a 3-fold resistant subline reported by Batist et al. (1989) , appear to utilise glutathione-related defences. In contrast to Mel R MCF-7 cells, the melphalan resistant cell line reported by Batist et al. does not demonstrate a change in melphalan uptake; resistance was attributed to an apparent change in DNA repair capacity.
In summary, MelR MCF-7 cells represent a useful in vitro model of melphalan resistance mediated by decreased capacity of the system L amino acid transporter. Melphalan is administered in a mileau of competitive inhibitors of its uptake. The potential utility of manipulation of amino acid transport systems in conjunction with melphalan chemotherapy was recently illustrated by a study which demonstrated increased melphalan uptake in tumour xenografts after circulating amino acid levels were lowered through fasting and administration of a protein-free diet (Groothuis et al., 1992) . Such strategies may ultimately improve the therapeutic effectiveness of melphalan. MelR provide an in vitro model for developing methods of specifically increasing melphalan uptake by modulating system L activity.
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